Inhibrx Biosciences, Inc. (INBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has a cash flow conversion efficiency ratio of -0.918x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.82 Million) by net assets ($36.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inhibrx Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhibrx Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Inhibrx Biosciences, Inc. for a breakdown of total debt and financial obligations.
Inhibrx Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Motus Holdings Ltd
JSE:MTH
|
0.273x |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
N/A |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
0.244x |
|
Pet Valu Holdings Ltd
TO:PET
|
0.590x |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
-0.090x |
|
Hagerty Inc
NYSE:HGTY
|
0.039x |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
0.174x |
|
Bittium Oyj
HE:BITTI
|
0.042x |
Annual Cash Flow Conversion Efficiency for Inhibrx Biosciences, Inc. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Inhibrx Biosciences, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $133.58 Million | $-194.41 Million | -1.455x | +67.25% |
| 2023-12-31 | $43.50 Million | $-193.31 Million | -4.444x | -123.75% |
| 2022-12-31 | $58.06 Million | $-115.30 Million | -1.986x | -29.52% |
| 2021-12-31 | $52.38 Million | $-80.32 Million | -1.533x | -141.26% |
| 2020-12-31 | $75.47 Million | $-47.97 Million | -0.636x | -285.38% |
| 2019-12-31 | $-93.57 Million | $-32.08 Million | 0.343x | -14.42% |
| 2018-12-31 | $-57.64 Million | $-23.09 Million | 0.401x | -52.10% |
| 2017-12-31 | $-22.42 Million | $-18.75 Million | 0.836x | +105.72% |
| 2016-12-31 | $1.24 Million | $-18.11 Million | -14.615x | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid… Read more